ArticleProstate cancer and prostatic diseases2018
Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.
Article in Prostate cancer and prostatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- Pooled it
- Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review.Molecular diagnosis & therapy · 2022Pooled it
- A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies.Prostate cancer and prostatic diseases · 2019Trial
- Clinical and MRI characteristics of germline pathogenic variant carriers diagnosed with prostate cancer.European radiology · 2026Article
- Delphi consensus of specialist radiologists on imaging criteria for gadolinium contrast use and whole-body MRI in prostate cancer.Insights into imaging · 2026Article
- Context-dependent role of digital rectal examination in a contemporary prostate biopsy cohort: differential predictive value with and without multiparametric magnetic resonance imaging.Prostate international · 2026Article
- PSA density for clinically significant prostate cancer detection: a retrospective cohort study on the influence of age and prostate volume.World journal of urology · 2026Article
- The Prognostic Value of Baseline PSA Density on Long-term Oncological Outcomes in Men with an Initial Negative Prostate Biopsy: Results from ERSPC Rotterdam.European urology open science · 2026Article
- Development of a quantitative multiparametric ultrasound and deep learning classifier for the detection of prostate cancer.European radiology · 2026Article
- Review
- The influence of age and the presence of prostate cancer on prostate volume, PSA and PSA density.BJU international · 2026Article
- Additional predictive value of systemic inflammation indices beyond prostate specific antigen density for clinically significant prostate cancer.BMC urology · 2026Article
- Article
- Article
- External Validation of the PROMOD Strategy, Combining PI-RADS Score and PSA Density, to Select Patients for Prostatic Biopsies.Research and reports in urology · 2026Article
- Blood inflammatory markers combined with tumor markers for differentiating benign prostatic hyperplasia from prostate cancer.Frontiers in medicine · 2026Article
- Analysis of gray zone PSA and PSAD correlated with PIRADS v2.1 in the MRI-US fusion prostate biopsy era: a retrospective bi-centre study.International urology and nephrology · 2025Article
- Object detection as an aid for locating the prostate in surface-based abdominal ultrasound images.Communications engineering · 2025Article
- Article
- Influence of m6A regulatory factor related to immune microenvironment on the prognosis of prostate cancer.Biomedical engineering online · 2025Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScreening for prostate cancer using prostate-specific antigen (PSA) alone leads to un-necessary biopsying and overdiagnosis. PSA density is easily accessible, but early evidence on its use for biopsy decisions was conflicting and use of PSA density is not commonly recommended in guidelines.
methodsWe analyzed biopsy outcomes in 5291 men in the population-based STHLM3 study with PSA ≥ 3 ng/ml and ultrasound-guided prostate volume measurements by using percentages and regression models. PSA density was calculated as total PSA (ng/ml) divided by prostate volume (ml). Main endpoint was clinically significant cancer (csPCa) defined as Gleason Score ≥ 7.
resultsThe median PSA-density was 0.10 ng/ml
conclusionsPSA-density might inform biopsy decisions, and spare some men from the morbidity associated with a prostate biopsy and diagnosis of low-grade prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.